Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative drugs function by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to food. By activating GLP-1 receptors in the pancreas, these agents increase insulin release and suppress glucagon rele

The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing variations